Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer

European Journal of Cancer

Volumn 43, Issue 7, 2007, Pages 1117-1124

  Vazquez martin, Alejandro ^a,b,c   Colomer, Ramon ^a,b,c   Menendez, Javier A ^a,b,c  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Breast cancer; Cytokines; ErbB 2; Gefitinib; GRO; HER2; IL 8

Indexed keywords

ALPHA CHEMOKINE; CXCL1 CHEMOKINE; CYTOKINE; ESTROGEN RECEPTOR; GEFITINIB; INTERLEUKIN 8;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSFECTION; GROWTH RELATED ONCOGENE; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE; ONCOGENE NEU; PATIENT MONITORING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40;

BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOBLOTTING; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2;

EID: 34247119113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.037     Document Type: Article

References (40)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
3. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., and Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 237 (1987) 178-182
4. Pierce J.H., Arnstein P., Di Marco E., et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6 (1991) 1189-1194
5. DiGiovanna M.P., Chu P., Davison T.L., et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res 62 (2002) 6667-6673
6. Xu R., Perle M.A., Inghirami G., Chan W., Delgado Y., and Feiner H. Amplification of Her-2/neu in Her-2/neu-overexpressing and nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15 (2002) 116-124
7. Alroy I., and Yarden Y. Biochemistry of HER2 oncogenesis in breast cancer. Breast Dis 11 (2000) 31-48
8. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
9. Harari D., and Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19 (2000) 6102-6114
10. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl 2 (2001) 1-13
11. Yu D., and Hung M.-C. Role of erbB2 in breast cancer chemosensitivity. BioEssays 22 (2000) 673-680
12. Pietras R.J., Arboleda J., Reese D.M., et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 (1995) 2435-2446
13. Alaoui-Jamali M.A., Paterson J., Al Moustafa A.E., and Yen L. The role of ErbB2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 75 (1997) 315-325
14. Wilson K.S., Roberts H., Leek R., Harris A.L., and Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 161 (2002) 1171-1185
15. Mackay A., Jones C., Dexter T., et al. cDNA microarray analysis of genes associated with ErbB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22 (2003) 2680-2688
16. White S.L., Gharbi S., Bertani M.F., Chan H.-L., Waterfield M.D., and Timms J.F. Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer 90 (2004) 173-181
17. Kumar-Sinha C., Ignatoski K.W., Lippman M.E., Ethier S.P., and Chinnaiyan A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63 (2003) 132-139
18. Gharbi S., Gaffney P., Yang A., et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 1 (2002) 91-98
19. Zhang D.-H., Tai L.K., Wong L.L., Sethi S.K., and Koay E.S.C. Proteomics of breast cancer: enhanced expression of cytokeratin19 in HER-2/neu-positive breast tumors. Proteomics 5 (2005) 1797-1805
20. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., and Koay E.S. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4 (2005) 1686-1696
21. Walser T.C., and Fulton A.M. The role of chemokines in the biology and therapy of breast cancer. Breast Dis 20 (2004) 137-143
22. Moore M.A. The role of chemoattraction in cancer metastases. BioEssays 23 (2001) 674-676
23. Murphy P.M. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345 (2001) 833-835
24. Benoy I.H., Salgado R., Van Dam P., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10 (2004) 7157-7162
25. De Larco J.E., Wuertz B.R., Rosner K.A., et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158 (2001) 639-646
26. Prest S.J., Rees R.C., Murdoch C., et al. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 17 (1999) 389-396
27. Freund A., Chauveau C., Brouillet J.P., et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22 (2003) 256-265
28. Lin Y., Huang R., Chen L., et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109 (2004) 507-515
29. Freund A., Jolivel V., Durand S., et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23 (2004) 6105-6114
30. Lin Y., Wang S.M., Lu W.M., and Huang R.P. Effect of interleukin-8 in cell invasion and proliferation of human breast cancer. Zhonghua Wai Ke Za Zhi 43 (2005) 1541-1544
31. Li J., and Sidell N. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer 117 (2005) 14-20
32. Youngs S.J., Ali S.A., Taub D.D., and Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71 (1997) 257-266
33. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1992) 85-95
34. Liu Y., el-Ashry D., Chen D., Ding I.Y., and Kern F.G. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34 (1995) 97-117
35. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
36. Kurokawa H., and Arteaga C.L. Inhibition of erbB (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 12 Suppl. (2001) 4436-4442
37. Huang R.P., Huang R., Fan Y., and Lin Y. Simultaneous detection of multiple cytokines from conditioned media and patient's sera by an antibody-based protein array system. Anal Biochem 294 (2001) 55-62
38. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006 May 22; [Epub ahead of print].
39. Colomer R., Montero S., Lluch A., et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6 (2000) 2356-2362
40. Esteva F.J., Cheli C.D., Fritsche H., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7 (2005) R436-R443